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Abstract 
Background: Until the early 2000s, people who inject drugs (PWID) in Québec had 
mainly been injecting powder cocaine and heroin. Since then, ethnographic studies have 
shown that the drug market has diversified, with crack and prescription opioids (PO) 
becoming increasingly available. This could have led to changes in drug use practices 
among PWID. The objectives of our study were to examine annual trends in injection of 
different drugs, crack smoking and frequent injection (FI), as well as relationships 
between injected drugs and FI.  
Methods: PWID are participants in the ongoing Québec SurvUDI surveillance system. 
PWID (past 6 months) were recruited in 2 urban and 6 semi-urban/rural sites. Each visit 
included a structured interview addressing drug use behaviours. Analyses were carried 
out using GEE methods. For trend analyses (2003-2014) on drugs and FI (number of 
injections ≥ upper quartile, previous month), the first annual interview was selected for 
PWID with multiple participations per year. Analyses on associations between FI and 
types of injected drugs were based on all interviews (2004-2014).  
Results: Crack/cocaine and heroin injection declined significantly, with prevalence ratios 
(PR) per year of 0.983 [95% confidence interval (CI): 0.980-0.986] and 0.979 (95% CI: 
0.969-0.990), while PO injection [PR=1.052 (1.045-1.059)], crack smoking [PR=1.006 
(1.001-1.012)], and FI (≥120 injections, previous month) significantly increased 
[PR=1.015 (1.004-1.026)]. Compared to PWID who injected crack/cocaine ± other drugs, 
the proportion of PWID reporting FI was higher among those who injected PO + 
heroin/speedball, crack/cocaine or other drugs (adjusted PR 2.29; 95% CI: 2.07-2.53) or 
PO only (aPR 1.72; 95%CI: 1.47-2.01). 
Conclusions: Changes that have occurred in the drug market are reflected in PWID’s 
practices. The high frequency of injection observed among PO injectors is of particular 
concern. Drug market variations are a challenge for health authorities responsible for 
harm reduction programs. 
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Introduction 
It is widely recognised that injection drug use is associated with a host of adverse health 
consequences. People who inject drugs (PWID) are at particularly high-risk for HIV and 
hepatitis C virus (HCV) infections (Patrick et al., 2001; Shepard, Finelli, & Alter, 2005; 
Mathers et al., 2008; Joint United Nations Programme on HIV/AIDS, 2012). Worldwide, 
in 2013, global HIV prevalence among PWID was 13.5%, and 52% of PWID were 
infected with HCV (United Nations Office on Drugs and Crime, 2015). In Eastern 
Central Canada, data from an epidemiological monitoring surveillance network reported 
that, for the 2003-2014 time period, 14.3% of participating PWID were HIV-infected and 
62.9% were HCV-positive (Leclerc, Roy, Morissette, Alary, & Parent, 2015). HIV and 
HCV incidence rates were estimated to be respectively 2.2 per 100 person-years for the 
period 1995-2014 and 22.1 per 100 persons-years for 1997-2014 (Leclerc et al., 2015). 
In Canada, cocaine injection has been identified for years as one of the main factors that 
have fueled the HIV and HCV epidemics among PWID (Tyndall et al., 2003; Bruneau, 
Roy, Arruda, Zang, & Jutras-Aswad, 2012; Kerr et al., 2016). The periods of erratic and 
high intensity use, characteristic of cocaine injection, are believed to be at cause (Tyndall 
et al., 2003; Kerr et al., 2016). Indeed, cocaine injection has been associated with higher 
daily number of injections and higher monthly injection frequency than heroin injection 
(Leri, Stewart, Tremblay, & Bruneau, 2004). This is of major concern because to this day 
powder cocaine remains the most commonly injected drug across the country and in 
Eastern Central Canada, with 64.3% and 72.0% of PWID respectively reporting cocaine 
injection in the previous six months (Public Health Agency of Canada, 2014; Leclerc et 
al., 2015). 
The drug market is constantly evolving, and Canada is not an exception in this regard. 
Unfortunately, at this time, there is no reliable information system about the illicit drug 
market in the country, with regard to production, purity, prices or types and amounts of 
drugs sold. Recent ethnographic studies, carried out in Montreal suggest that the street 
drug market has been changing significantly since the early 2000s, with a notable 
increase in the availability of crack cocaine [a form of cocaine usually inhaled] and 
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prescription opioids (PO) (Roy, Arruda, & Bourgois, 2011; Roy et al., 2012; Roy & 
Arruda, 2015). Empirical data seem to confirm that these market changes have occurred 
not only in Montréal but throughout the province of Québec, the setting of the present 
study. 
Previous literature has highlighted the influence of drug markets on drug use patterns, 
namely the types of drugs and routes of drug administration being used in the population. 
A report published in 1993 by the United Nations Office on Drugs and Crime described 
how political and legal changes in various regions of the world brought about variations 
in the drug market, which in turn led to the spread of injection drug use in many areas 
(Stimson, 1993). One example stated by the author is the spread of heroin injection that 
occurred in Asian countries in the 50s and later, mostly in drug-producing areas and 
along drug transit routes.  Heroin availability led to transitions from opiate inhalation to 
injection among societies where smoked opium use was a tradition.  Another eloquent 
example presented in the report is the drug injection peaks in the United States in the late 
60s that coincided with abundant supplies of heroin from the French Connection and 
Mexico. Conversely, heroin shortages have also been shown to impact patterns of drug 
use. Following a sustained heroin shortage in 2001 in Australia, researchers documented 
several changes in drug use patterns in the population which included a reduction of the 
prevalence of injection drug use and a shift in the types of drugs injected among PWID 
from heroin to stimulants, most notably cocaine and methamphetamine (Topp, Day, & 
Degenhardt, 2003).  In Great Britain, during a significant heroin shortage between 2010 
and 2011, researchers found that heroin users were transitioning to other types of drugs, 
most notably benzodiazepines and crack cocaine (Harris, Forseth & Rhodes, 2015). In 
Hungary, the increasing availability of synthetic cathinones accompanied by a decrease 
of heroin availability has led to a decrease of heroin injection and an increase of synthetic 
cathinones injection among PWID (Péterfi, Tarján, Horváth, Cseztregi & Nyírády, 2014). 
Furthermore, a number of studies have shown that the arrival of crack cocaine in the 
street-drug market has led to a decline in injection drug use in several regions of the 
world (Leonard et al., 2008; Bourgois, 2003a; Bourgois, 2003b; Inciardi et al., 2006; van 
Ameijden & Coutinho, 2001; Mesquita et al., 2001).  
5 
 
Of course, the drug market is not the only determinant of drug use patterns in a 
population, but it has an undeniable influence. It is plausible that observed changes in the 
street drug market landscape have modulated the drug use patterns and injection practices 
of PWID in Québec, most notably in the type of drugs injected and injection frequency. 
Updated data on drug use trends and injection frequency could allow re-evaluation of 
types of sterile injection material available and coverage of prevention programs to better 
prevent parenteral transmission of HIV and HCV (Bluthenthal, Anderson, Flynn, & Kral, 
2007; Vickerman, Martin, Turner, & Hickman, 2012). The objectives of the present paper 
are twofold:  1) to examine the annual trends of injected drugs, crack smoking and 
frequency of injection among PWID in the province of Québec, and 2) to study the 
relationships between types of injected drugs and frequent injection (FI). 
Methodology 
This study was carried out using data from the SurvUDI network, whose complete 
methodology has been previously described (Hankins et al., 2002). Briefly, the SurvUDI 
network is a second-generation surveillance program for HIV, HCV and risk behaviours 
among PWID in Eastern Central Canada. The ongoing network was implemented in 1995 
and targets hard-to-reach, mostly out-of-treatment PWID. Eligibility criteria include 
being 14 or older, injecting at least once within the past 6 months, speaking French or 
English, and being able to provide informed consent. For the province of Québec, 
participants are recruited in 2 urban and 6 semi-urban/rural sites, mainly in harm 
reduction programs. Others are recruited in drop-in centres, detention centres, 
detoxification clinics, and rehabilitation programs. Each visit involves obtaining the 
participant’s informed consent, completing an interviewer-administered questionnaire 
and collecting a saliva sample for HIV and HCV antibody testing. Participants are 
encouraged to complete interviews at 6-month intervals. They are given a stipend ranging 
from CAN$5 to $10 at the end of each visit. All procedures have been approved by the 
ethics committee of the CHU de Québec – Université Laval. 
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Variables 
Types of injected drugs (including PO substances) and crack smoking are assessed for the 
six months prior to the interview since 2003, and for the last month since 2004. A list of 
several drugs is shown to participants, who are asked to specify if they have injected any 
of the listed drugs prior to the interview. For the analyses related to the second objective, 
since participants can inject several different substances, five mutually exclusive 
categories were created: 1) prescription opioids only, 2) prescription opioids with any 
other drug be it heroin (including speedball), crack/cocaine or other drugs (ex. 
amphetamine-type stimulants, benzodiazepines, ketamine, etc.), 3) heroin/speedball 
with/without crack/cocaine or other drugs, 4) crack/cocaine with/without other drugs, and 
5) other drugs only. 
 
To assess injection frequency, participants are asked how many times they have injected 
during the last month. High frequency injection corresponds to the values in the upper 
quartile of the number of injections reported during the month. Sociodemographic 
characteristics include sex, age, residential status (homeless or not) and the region where 
the interview took place (urban or semi-urban). Homelessness is defined as having 
slept/lived at least once in the last six months in the street, a squat, an emergency shelter, 
or any place unfit for human habitation such as a car or a subway station.  
Analyses 
Trends analyses are based on visits that took place between January 2003 and December 
2014. All PWID who participated in SurvUDI during that time period were selected for 
the trends analyses performed on types of injected drugs and crack smoking in the six 
months prior to interview. Analyses of trends of FI are based on the subsample of PWID 
who injected in the previous month. Only the first annual interview was selected for 
PWID with multiple participations per year.  
Analyses of the association between FI and drugs injected in the previous month were 
based on all interviews carried out between March 2004 and December 2014, and 
included all visits where the type of drugs injected and injection in the previous month 
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were reported. FI was treated as a dependent variable; co-variables included in the 
modelling were age, sex, crack smoking and homelessness.  
Descriptive statistics included means and standard deviation (SD) and medians and 
corresponding interquartile ranges (IQR) for continuous variables, and frequency 
distributions for categorical variables. Principal analyses were carried out using a 
generalized estimating equations (GEE) method (Liang & Zeger, 1986). All prevalence 
ratios were estimated using log-binomial regression, and 95% Wald confidence intervals 
were calculated. For trends analyses, year of observation was treated as a continuous 
variable. Additional exploratory analyses using nonparametric generalized additive 
models with splines smoothers made it possible to identify sub-periods of significant 
fluctuations within the full study period (Hastie & Tibshirani, 1990). Then, separated 
GEE models for each identified sub-period were also examined. 
Results 
A total of 5,137 PWID participated in the SurvUDI network between January 2003 and 
December 2014 (Table 1). At first visit, the sample was mainly comprised of men 
(76.4%) and participants aged 25 years or older (82.9%). The most reported injected drug 
was crack/cocaine (with/without speedball) (86.6%) followed by PO (47.4%), heroin 
(with/without speedball) (34.3%) and other drugs (12.0%) and two thirds reported crack 
smoking.  More than a quarter of participants (29.8%) reported FI (≥120/month). 
Trends analyses of injected drugs and crack smoking in the last six months for 2003 to 
2014 were based on a total of 9,355 visits (Figure 1). Global trends show that 
crack/cocaine and heroin injection significantly declined, with prevalence ratios (PR) per 
year of 0.983 [95% confidence interval (CI): 0.980-0.986] and 0.979 (95% CI: 0.969-
0.990), while PO injection [PR=1.052 (1.045-1.059)] and crack smoking [PR=1.006 
(1.001-1.012)] significantly increased. FI in the last month (8,386 visits) also rose 
significantly [PR=1.015 (1.004-1.026)]. Further analyses show that these overall trends 
were the result of significant fluctuations over the study period (Table 2). PO injection 
and FI increased mainly between 2003 and 2008 whereas heroin injection followed the 
opposite trend mostly between 2003 and 2007. Crack smoking increased between 2003 
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and 2008 and then declined slightly while crack/cocaine injection, that had first remained 
stable, decreased significantly between 2007 and 2014.  
For the period 2004 to 2014, analyses of the association between FI and injected drugs in 
the previous month were based on 9,077 visits (4,363 PWID) (Table 3). Homelessness 
was reported in 39.3% of visits and crack smoking (in the previous month) in 53.0%; 
89.7% of interviews were carried out in urban sites. Observed frequencies for the five 
categories of injected drugs in the month prior to interview were as follows: 1) PO only: 
9.0% of visits; 2) PO + heroin/speedball, crack/cocaine or other drugs: 36.4%; 3) 
heroin/speedball ± crack/cocaine or other drugs: 9.9%; 4) crack/cocaine ± other drugs: 
44.4%; and 5) other drugs only: 0.3%. FI was reported in 29.9% of all visits. Finally, 
compared to PWID who injected crack/cocaine ± other drugs, the proportion of PWID 
reporting frequent injection was higher among those who injected PO + heroin/speedball, 
crack/cocaine or other drugs (adjusted PR 2.29; 95% CI: 2.07-2.53), or PO only (aPR 
1.72; 95% CI: 1.47-2.01), adjusted for age, sex, homelessness and crack smoking.  
Discussion 
Our results indicate that the substances used by PWID in Québec changed from 2003 to 
2014. Even though fluctuations occurred during that time-period, prevalence of 
crack/cocaine and heroin injection decreased from 91.8% to 72.1% and from 44.0% to 
34.3% respectively while prevalence of crack smoking and PO injection increased from 
52.5% to 60.4% and from 29.8% to 58.6% respectively. These results are analogous with 
the drug situation in Vancouver, in Western Canada, where researchers documented 
major changes in drug use trends over a 15-year period (1996-2011) among people who 
use drugs (Urban Health Research Initiative, 2013). Those researchers found that both 
daily cocaine injection and daily heroin injection decreased substantially, while daily 
crack smoking and PO injection increased.  
Explaining changes in drug use trends may be a complicated task. In Québec, previous 
research work helps shed light on the present findings. According to a mixed-method 
study conducted in Montréal that included epidemiological and ethnographic data, crack 
smoking became highly prevalent among regular cocaine users, including those who used 
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to inject powder cocaine, after crack cocaine became more widely accessible in the early 
2000s (Roy et al., 2012). Although powder cocaine was still available, its accessibility 
decreased as new selling strategies limited “street-corner” transactions in favour of 
telephone orders. Therefore, whereas crack was not previously accessible, PWID now 
had options (powder or crack cocaine). Aside from these market-related factors, what we 
could consider as new social norms in the drug milieu also may have played a role in the 
observed changes in drug use patterns. In fact, another ethnographic study conducted in 
crack houses (piaules) in a Montréal neighbourhood during the same time period revealed 
that injection was prohibited in those settings and crack was the only form of cocaine 
sold (Roy & Arruda, 2015). While the drug dealers’ decision to only sell crack was 
motivated by generating higher profits, it also aimed to eradicate the negative 
consequences associated with injection drug use, namely discarded needles and drug 
overdoses that can draw police attention, which is bad for business. 
Our findings that show increased PO injection are consistent with the growing 
availability of PO in the community. As is the case elsewhere in North America, a sharp 
rise in opioid analgesic prescriptions has been observed over the last several years in 
Canada (Fischer, Jones, & Rehm, 2014). This phenomenon has led to a large increase in 
non-medical use of PO in the population (Fischer, Gooch, Goldman, Kurdyak, & Rehm, 
2014). An ethnographic study conducted in Montréal reported that diverted PO (mainly 
hydromorphone in the form of tablets or capsules) were easily accessible on the streets 
and some doses could be bought for a fairly low price. Conversely, in addition to being 
more expensive, heroin had to be telephone-ordered and a limited number of PWID had 
access to the dealers’ phone numbers. These differences in accessibility and selling 
strategies may help explain the evolving trends of each substance (Roy et al., 2011). This 
particular situation where the decrease of heroin injection may be due to the growing 
availability/accessibility of PO seems to contrast with the experience in the USA where 
increases in PO misuse have led to an increase of heroin use/injection mainly due to the 
lower cost and easier access of heroin (Jones, 2013; Lipari & Hughes, 2015; Mars, 
Bourgois, Karandinos, Montero, & Ciccarone, 2014; Kolodny et al., 2015).   
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Our trends results find an echo in previous literature documenting changing patterns of 
drug use. Sharp decreases in cocaine injection following the introduction of crack cocaine 
have been documented elsewhere (Bourgois, 2003a; Inciardi et al., 2006; Mesquita et al., 
2001). Changes in drug trafficking and the fear of HIV/AIDS were mentioned as 
mechanisms modulating the new drug use patterns. However, unlike the decline of heroin 
injection documented in Australia, Great Britain and Hungary, that was accompanied by 
an increase of stimulant use (Topp et al., 2003; Harris, Forseth & Rhodes, 2015; Pétrefi et 
al., 2014), the decrease in heroin injection in Québec does not appear to be due to a 
heroin shortage. Rather, it seems to be attributable to the growing 
availability/accessibility of PO and selling strategies. It should be noted that PWID in 
Québec did not transition from one pharmacological class of injected drugs to another. 
Rather, Québec has been witnessing a diversification of injectable substances belonging 
to the same pharmacological class (opioids: heroin and PO) and of the available forms of 
the same substance (powder cocaine and crack). Once dominated by powder cocaine and 
heroin, crack and PO are now some of the most used substances by PWID in Québec. 
Since high frequency of injection can render PWID more vulnerable to various negative 
health outcomes (Philipps & Stein, 2010; Yao et al., 2009; Tyndall et al., 2003; Nelson et 
al., 2002; Thorpe, Ouellet, Levy, Williams, & Monterroso, 2000), one particularly 
worrisome finding of the present study is that FI (≥120 injections in the previous month) 
rose slightly between 2004 and 2014, from 24.2% to 32.3%. This increase occurred 
despite the fact that cocaine injection, which can generate a high number of injections 
(Tyndall et al., 2003; Leri et al., 2004), decreased during the same time period. In fact, 
our results show that the proportion of PWID reporting FI was highest among those who 
injected PO. It is possible that the increase in crack smoking among PWID has led to a 
reduction in the number of cocaine injections. Also, it seems logical that PO are 
associated with more frequent injections since opioids cause physical dependence that 
compels PWID to inject daily.  
Although heroin and PO are pharmacologically similar (Compton, Jones, & Baldwin, 
2016), our results indicate that FI was more prevalent among PWID who injected PO. A 
previous ethnographic study may help understand this observation (Roy et al., 2011). 
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When compared with powder heroin available in Québec, PO can be bought in small 
doses for a price as low as CAN$5 (e.g. Dilaudid© 4 mg or Hydromorph-Contin© 6 mg). 
In contrast to the minimal heroin dose that can be purchased for CAN$25 and that 
produces an effect lasting several hours, small PO doses produce a suboptimal effect that 
requires users to inject several times a day to keep withdrawal symptoms at bay. 
Furthermore, when PO users are able to buy optimal doses (e.g. Hydromorph-Contin© 30 
mg), multiple injections are necessary since the volume of water to dissolve the pills or 
capsules exceeds the capacity of syringes distributed by needle exchanges programs 
(selected in the prior context of cocaine and heroin predominance). In either case, PO 
injection can lead to FI. 
Changes in the drug use trends of PWID in Québec seem largely due to the dynamic 
nature of street-drug markets. Indeed, drug markets are part of environmental and 
structural factors that shape drug use patterns (Rhodes, Singer, Bourgois, Friedman, & 
Strathdee, 2005). They can significantly modulate the influence of individual and social 
factors on drug use behaviours (Sterk & Elifson, 2000; Ciccarone, 2009; Gamella, 1994; 
Stimson & Choopanya, 1998). In a study conducted in Sao Paulo, Brazil, a decline in 
HIV prevalence was accompanied by a decrease in cocaine injection frequency 
concurrent with an increase in crack smoking (Mesquita et al., 2001). However, this is 
not what has happened in Québec. The high frequency of injection among PWID who 
inject PO is of particular concern. Although little research has been conducted, some 
studies have found associations between PO injection and HIV/HCV transmission 
(Bruneau et al., 2012; Lankenau, Kecojevic, & Silva, 2015; Conrad et al., 2015; Zibbell, 
Hart-Malloy, Barry, & Flanigan, 2014). Of particular interest, a prospective cohort study 
of PWID conducted in Montréal observed that PO injectors who did not inject heroin 
were more likely to become infected with HCV, whereas no association was found for 
participants using both drugs (Bruneau et al., 2012). In addition, compared to non-PO 
injectors, PO injectors exhibited greater injection risk behaviours such as syringe sharing 
and FI. Clearly more research is needed in this area.  
This study presents some limitations. Our findings should only be generalized to PWID 
with more problematic behaviours who attend harm reduction community-based 
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resources. Furthermore, self-reported behavioural measures may lead to desirability and 
recall biases that could have led to imprecisions in prevalence estimates. However, 
previous studies have shown the validity and reliability of IDUs’ self-reported behaviours 
(Darke, 1998; Goldstein et al., 1995). 
In summary, our results indicate that the drug use patterns of PWID in Québec have 
changed over time, seemingly due to drug market changes. This has resulted in the 
reduction in certain risk behaviours but the exacerbation of others. Drug market 
variations pose major challenges to public health authorities in their endeavour to fully 
cover the needs for safe injection equipment and other prevention programs. Therefore, it 
is essential to follow drug use trends through drug market surveillance program data.  
The results of the present study pose important challenges for optimal coverage of harm 
reduction programmes. The growing popularity of PO injection is particularly 
challenging for public health authorities and community-based organizations working 
among PWID since previous literature has found associations between PO 
misuse/injection and serious health-risks, most notably fatal overdoses (Jones, Mack & 
Paulozzi, 2010; Rudd, Aleshire, Zibbell & Gladden, 2016; Fischer, Jones & Rehm, 2013) 
and parenteral transmission of HIV/HCV (Bruneau et al., 2012; Lankenau et al., 2015; 
Conrad et al., 2015; Zibbell et al., 2014). One of the often mentioned policy change to 
counter PO-related health risks in the general population is to establish effective 
prescription drug monitoring programs (PDMP) and safe guidelines for prescribing PO. 
These measures could reduce the prevalence of PO addiction/injection and the amount of 
PO being diverted for non-medical use. However, in a drug using population where 
opioid addiction/injection is prevalent, concentrating policies on reducing the diverted 
supply of PO could have potential negative effects. For example, Mars and colleagues 
(2014) observed that supply-side changes that limited the sourcing of diverted 
OxyContin© prompted some PO users to transition to heroin. As other authors have 
suggested (King, Fraser, Boikos, Richardson, & Harper, 2014; Kolodny et al., 2015), we 
strongly believe that PDMP and better prescribing practices should be complemented 
with a better coverage of harm reduction strategies in order to reduce PO-related health 
risks. Among these, coverage of medication-assisted therapies (MAT) should be 
13 
 
maximised in order to decrease the pool of PO-addicted people. In addition, MAT could 
have the potential to reduce the risks of overdose deaths (Schwartz et al., 2013). 
Expanding the availability and accessibility of naloxone kits (an opioid antagonist) to 
laypersons could prevent opioid-related fatal overdoses (Walley et al., 2013). 
Furthermore, in order to prevent the parenteral transmission of HIV/HCV, coverage of 
sterile injection equipment distribution has to be evaluated, given the growing popularity 
of PO injection and its high injection frequency. Also, the characteristics of the 
equipment distributed have to be reviewed to ensure that they meet the requirements for 
injection of PO formulas that require high volumes of water. In addition to these harm 
reduction strategies, interventions aimed at preventing PO injection should be tailored in 
collaboration with PWID peers. Finally, it should be noted that closely following drug 
use behaviours, including injection drug use trends, is crucial to adapt harm reduction 
programmes and prevent HIV and HCV infections among PWID. 
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Figure 1. Trends analyses of drugs injected, crack smoking and frequent injection  
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Table 1 
Characteristics of the 5,137 PWID at first visit. 
Characteristics No. % 
Sociodemographic   
Male gendera 3,908 76.4 
Age ≥25 years 4,257 82.9 
Age (mean ± SD)  35.7 ± 10.2 - 
Age (median [IQR]) 36 [27-44] - 
Homelessnessb,c 2,007 39.1 
Urban sites 4,208 81.9 
   
Drug usec   
Prescription opioids injection 2,434 47.4 
Heroin injectiond 1,763 34.3 
Crack/cocaine injectiond 4,450 86.6 
Other drugs injectione 617 12.0 
Crack smokingf 3,272 63.8 
   
Injection practicesg   
No. of injections (mean ± SD) 108.0 ± 172.9 - 
No. of injections (median [IQR]) 50 [12-120] - 
Frequent injection (≥120/month) 1,337 29.8 
Abreviations: SD, standard deviation; IQR, interquartile range. 
a 24 missing values. 
b 10 missing values. 
c In the six months prior to interview. 
d Including speedball. 
e Other drugs: amphetamine-type stimulants, benzodiazepines, ketamine, etc. 
f 5 missing values. 
g In the month prior to interview, among those who had injected drugs during that month, N=4,484 PWID. 
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Table 2. 
Trends analyses of drugs injected, crack smoking and frequent injection: sub-periods of 
fluctuations. 
 Sub-
period 
% 
beg.a 
% 
endb 
PRc (95% CI)  
Prescription opioids injectiond 2003-2008 29.8 55.0 1.125 (1.101-1.150) *
* 
 2008-2014 55.0 58.6 1.007 (0.994-1.019)  
Heroin injectiond,e 2003-2007 44.0 23.3 0.847 (0.820-0.875) *
* 
 2007-2014 23.3 34.3 1.017 (1.000-1.035)  
Crack/cocaine injectiond,e 2003-2007 91.8 91.3 1.000 (0.992-1.006)  
 2007-2014 91.3 72.1 0.971 (0.966-0.976) *
* 
Crack smokingd,f 2003-2008 52.5 71.8 1.063 (1.049-1.078) *
* 
 2008-2014 71.8 60.4 0.986 (0.976-0.997) * 
Frequent injectiong 
(≥120/month) 
2003-2008 24.2 33.2 1.040 (1.008-1.072) * 
2008-2014 33.2 32.3 0.986 (0.964-1.008)  
Abreviations: PR: prevalence ratio; CI, confidence interval. ** p<0.0001, * p<0.05 
a Percentage at the beginning of the sub-period. 
b Percentage at the end of the sub-period. 
c Year treated as a continuous variable, separated models for each sub-period. 
d In the six months prior to interview, N=9,355 visits. 
e Including speedball. 
f 7 missing values. 
g In the month prior to interview, among those who had injected drugs during that month, N=8,386 visits. 
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Table 3. 
Association between frequent injection (≥120/month) and drugs injected in the month prior to 
interview (N=9,077 visits). 
Drugs category No. % Crude 
PR 
Adjusteda PR 
(95% CI) 
 
Crack/cocaine ± other drugsb 4,028 44.4 Ref Ref  
Prescription opioids only 820 9.0 1.75 1.72 (1.47-2.01) *
* 
Prescription opioids + 
heroin/speedball, crack/cocaine or 
other drugsb 
3,303 36.4 2.40 2.29 (2.07-2.53) *
* 
Heroin/speedball ± crack/cocaine or 
other drugsb 
897 9.9 1.09 1.09 (0.92-1.28)  
Other drugsb only 29 0.3 0.18 0.18 (0.03-1.23)  
Abreviations: PR: prevalence ratio; CI, confidence interval; Ref, reference. ** p<0.0001 
a PR adjusted for age, sex, homelessness and smoking crack in the month prior to interview, N=9,016 visits 
(61 missing values). 
b Other drugs: amphetamine-type stimulants, benzodiazepines, ketamine, etc. 
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